Cargando…
LRRK2 and ubiquitination: implications for kinase inhibitor therapy
Pathogenic mutations and risk variants in LRRK2 (leucine-rich repeat kinase 2) represent the most common genetic cause of familial and sporadic PD (Parkinson's disease). LRRK2 protein is widely expressed throughout the brain and the periphery. Structurally, LRRK2 contains several functional dom...
Autor principal: | Melrose, Heather L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613699/ https://www.ncbi.nlm.nih.gov/pubmed/26341487 http://dx.doi.org/10.1042/BJ20150785 |
Ejemplares similares
-
‘Up with the LRRK’: a phosphorylated Rab10 assay for evaluation of LRRK2 activity and inhibitor engagement
por: Eyers, Patrick A.
Publicado: (2016) -
Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia
por: Maekawa, Tatsunori, et al.
Publicado: (2016) -
Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity
por: Kluss, Jillian H., et al.
Publicado: (2018) -
LRRK2 dephosphorylation increases its ubiquitination
por: Zhao, Jing, et al.
Publicado: (2015) -
Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease
por: Lee, Byoung Dae, et al.
Publicado: (2010)